E. Stadberg et al., LOW-DOSES OF 17-BETA-ESTRADIOL AND NORETHISTERONE ACETATE AS CONTINUOUS COMBINED REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN - LIPID METABOLIC EFFECTS, Menopause, 3(2), 1996, pp. 90-96
Our objective was to investigate the effects on serum and lipoprotein
lipids of low doses of 17 beta-estradiol (E(2)) and norethisterone ace
tate (NETA) administered as continuous combined hormone replacement th
erapy (HRT) in postmenopausal women. A one-center prospective randomiz
ed double-blind comparison of three hormone replacement combinations w
as carried out during 12 months. Subjects were 60 healthy postmenopaus
al women with climacteric symptoms, Treatment was continuous combined
regimens as one tablet every day given to three treatment groups denot
ed group A (1 mg E(2) + 0.25 mg NETA), group B (1 mg E(2) + 0.5 mg NET
A), and group C (2 mg E(2) + 1 mg NETA). A significant decrease in tot
al cholesterol (0.4-0.61 mmol/L) and low-density lipoprotein (LDL)-cho
lesterol (0.12-0.33 mmol/L) was found in all groups. High-density lipo
protein (HDL)-cholesterol decreased (0.11-0.15 mmol/L) after 12 months
but the HDL/LDL ratio remained unchanged. Serum triglyceride levels w
ere reduced in all groups (0.07-0.31 mmol/L) but the reduction did not
reach statistical significance. The levels of serum lipoprotein(a) sh
owed a slight reduction at the end of the study (10-14 mg/L). Small ch
anges occurred in apolipoprotein-A1 levels. Apolipoprotein-B increased
in group B (p < 0.05) and was unchanged in groups A and C. Low doses
of E(2) and NETA as continuous combined HRT induced small metabolic ef
fects. No significant differences were observed between the treatment
groups, The significance of the changes in lipid metabolism in elderly
women on long-term therapy cannot be fully evaluated from our study b
ut has to be confirmed further in larger epidemiological studies.